Forma Therapeutics, Inc, a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, announced recently that the company’s investigational IDH1m inhibitor, olutasidenib, demonstrated a preliminary disease control rate of 50% in heavily pre-treated patients with predominantly enhancing, recurrent mIDH1… Read More
Scottsdale, Arizona, May 27, 2020 – Imaging Endpoints announced today that it has supported two additional U.S. Food and Drug Administration (FDA) approvals this month for new, life-saving therapies. The two New Drug Application (NDA) approvals, for two of the… Read More
Whether it is tumor blood flow, tumor microenvironment, or radiomics, Imaging Endpoints is at the leading edge of imaging science and is redefining the role an imaging core lab can provide in product development. It is one more way that… Read More
Radiomics is a rapidly growing field of radiology that extracts high-dimensional data from standard of care CT images to define a novel set of quantifiable imaging patterns – an imaging biomarker. Imaging Endpoints is a pioneer and global leader in… Read More
Imaging Endpoints has a great work environment and is leading the industry in our novel imaging technology. If you are looking for a position with great benefits and great opportunity to advance at the fastest-growing company in the imaging CRO… Read More
Featured Webinar:
Radiologic Analysis of COVID-19 Infection
June 23, 2020
